Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study

被引:21
|
作者
Spadea, A. [1 ]
Unim, B. [2 ]
Colamesta, V. [2 ]
Meneghini, A. [1 ]
D'Amici, A. M. [1 ]
Giudiceandrea, B. [1 ]
La Torre, G. [2 ,3 ]
机构
[1] RM A Local Hlth Unit, Rome, Italy
[2] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy
[3] Eleonora Lorillard Spencer Cenci Fdn, Rome, Italy
关键词
TIV; MF59; ATIV; Elderly; Influenza; Hospitalization; ANTIBODY-RESPONSE; HEALTH; HOSPITALIZATION; COMMUNITY; MORTALITY; CHILDREN; SAFETY;
D O I
10.1016/j.vaccine.2014.07.077
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Influenza illness is an important public health problem and annual vaccination is globally recommended for high risk populations. Objective: The aim was to evaluate and compare the effectiveness of influenza vaccines in reducing hospitalizations for influenza or pneumonia during two influenza seasons in the elderly. Methods: A case-control study was performed, using administrative database of the Local Health Unit Roma-A (LHU RM-A). The included subjects were at least 65 years old and residing in one of the four districts of the LHU. The cases were hospitalized for influenza or pneumonia during influenza season in the years 2010-2011 and 2011-2012. The controls were hospitalized in the same period, but not for influenza or pneumonia. The subjects were immunized with the trivalent inactivated influenza vaccine (TIV) in the first influenza season (2010-2011) and with the adjuvanted influenza vaccine MF59 (ATIV) in the second season (2011-2012). Results: A total of 269 cases and 1247 controls were included for the 2010-2011 influenza season, and 365 cases and 1227 controls were selected for the 2011-2012 season. Up to 63.6% cases and 53.5% controls in the 2010-2011 season and 78.6% of cases and 64.1% of controls in the 2011-2012 season have not been vaccinated. Female gender and high educational level were protective factors for hospitalization. Subjects over 75 years were at high risk of hospitalization compared to 65-74 years olds. Influenza vaccination reduced significantly hospitalization in both seasons. In subjects with 65-74 years TIV was more effective than ATIV; vice versa for those over 75 years old. Discussion and conclusion: TIV and ATIV reduce hospitalization for influenza or pneumonia with a variable degree of protection in different age groups. In particular, ATIV is more effective in individuals over 75 years old. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5290 / 5294
页数:5
相关论文
共 50 条
  • [1] The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly
    Van Buynder, P. G.
    Konrad, S.
    Van Buynder, J. L.
    Brodkin, E.
    Krajden, M.
    Ramler, G.
    Bigham, M.
    VACCINE, 2013, 31 (51) : 6122 - 6128
  • [2] Effectiveness of trivalent inactivated influenza vaccine in influenza-related hospitalization in children: A case-control study
    Joshi, Avni Y.
    Iyer, Vivek N.
    Hartz, Martha F.
    Patel, Ashok M.
    Li, James T.
    ALLERGY AND ASTHMA PROCEEDINGS, 2012, 33 (02) : E23 - E27
  • [3] Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial
    Loeb, Mark
    Russell, Margaret L.
    Kelly-Stradiotto, Caralyn
    Fuller, Nola
    Fonseca, Kevin
    Earn, David J. D.
    Chokani, Khami
    Babiuk, Lorne
    Neupane, Binod
    Singh, Pardeep
    Pullenayegum, Eleanor
    VACCINE, 2021, 39 (47) : 6843 - 6851
  • [4] Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine
    Song, Joon Young
    Cheong, Hee Jin
    Noh, Ji Yun
    Seo, Yu Bin
    Choi, Won Suk
    Cho, Geum Joo
    Hwang, Taik Gun
    Kim, Woo Joo
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (09) : 1591 - 1597
  • [5] Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: A case-control study
    Joshi, Avni Y.
    Iyer, Vivek N.
    St Sauver, Jennifer L.
    Jacobson, Robert M.
    Boyce, Thomas G.
    VACCINE, 2009, 27 (33) : 4457 - 4461
  • [6] Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly
    Thorrington, Dominic
    van Leeuwen, Edwin
    Ramsay, Mary
    Pebody, Richard
    Baguelin, Marc
    VACCINE, 2019, 37 (15) : 2051 - 2056
  • [7] AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
    McElhaney, Janet E.
    Beran, Jiri
    Devaster, Jeanne-Marie
    Esen, Meral
    Launay, Odile
    Leroux-Roels, Geert
    Ruiz-Palacios, Guillermo M.
    van Essen, Gerrit A.
    Caplanusit, Adrian
    Claeyst, Carine
    Durandt, Christelle
    Duvalt, Xavier
    El Idrissit, Mohamed
    Falseyt, Ann R.
    Feldmant, Gregory
    Freyt, Sharon E.
    Gaitiert, Florence
    Hwang, Shinn-Jang
    Innist, Bruce L.
    Kovact, Martina
    Kremsnert, Peter
    McNeill, Shelly
    Nowakowskit, Andrzej
    Richardust, Jan Hendrik
    Trofat, Andrew
    Oostvogels, Lidia
    LANCET INFECTIOUS DISEASES, 2013, 13 (06) : 485 - 496
  • [8] Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
    Hu, Yuemei
    Chu, Kai
    Lavis, Nathalie
    Li, Xiaoling
    Liang, Bill
    Liu, Shuzhen
    Shao, Ming
    Shu, Jean-Denis
    Tabar, Cynthia
    Samson, Sandrine
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) : 1066 - 1069
  • [9] MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications
    Patel, Sanjay S.
    Bizjajeva, Svetlana
    Heijnen, Esther
    Oberye, Janine
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 85 : S18 - S25
  • [10] Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population
    Marbaix, Sophie
    Dauby, Nicolas
    Mould-Quevedo, Joaquin
    EXPERT REVIEW OF VACCINES, 2023, 22 (01) : 608 - 619